financetom
Business
financetom
/
Business
/
CarParts.com Q2 sales miss estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CarParts.com Q2 sales miss estimates
Aug 12, 2025 1:34 PM

Overview

* CarParts.com ( PRTS ) Q2 net sales rise 5% to $151.9 mln, missing estimates

* Net loss widens to $12.7 mln due to lower margins, higher marketing spend

* Company exploring strategic alternatives, including potential sale or investments

Outlook

* CarParts.com ( PRTS ) is not providing 2025 guidance due to strategic evaluations

* Company expects $10 mln annualized cost savings from AI and automation

* CarParts.com ( PRTS ) anticipates margin and efficiency gains from strategic initiatives

Result Drivers

* ECOMMERCE DEMAND - Increased consumer demand through primary eCommerce channel drove sales growth

* MARKETPLACE SOFTNESS - Continued softness in marketplace sales channel partially offset sales growth

* MARGIN PRESSURE - Gross margin decreased due to product mix and tariff impacts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Miss $151.95 $153.50

mln mln (2

Analysts

)

Q2 Net -$12.71

Income mln

Q2 -$3.12

Adjusted mln

EBITDA

Q2 Gross $49.78

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the auto vehicles, parts & service retailers peer group is "buy"

* Wall Street's median 12-month price target for Carparts.Com Inc ( PRTS ) is $1.90, about 53.2% above its August 11 closing price of $0.89

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute
Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute
Oct 7, 2024
12:40 PM EDT, 10/07/2024 (MT Newswires) -- Liquidia ( LQDA ) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics ( UTHR ) for a review of previous rulings over a patent infringement dispute between the two companies. The high court's rejection of United Therapeutic's petition means that the...
Supreme Court seeks US views on Republican AGs challenge to climate change cases
Supreme Court seeks US views on Republican AGs challenge to climate change cases
Oct 7, 2024
Oct 7 (Reuters) - The U.S. Supreme Court on Monday asked President Joe Biden's administration to weigh in on whether the justices should allow 19 Republican-led states to try to block five Democratic-led states from pursuing lawsuits over climate change against major oil and gas companies in state courts. The request for input from U.S. Solicitor General Elizabeth Prelogar on...
GM resumes production after hurricane-related supplier issue
GM resumes production after hurricane-related supplier issue
Oct 7, 2024
(Reuters) - General Motors ( GM ) said Monday it is resuming production at two assembly plants in Texas and Michigan after it temporarily halted production at the plants last week because of impacts to its suppliers due to Hurricane Helene. GM canceled production at Flint Assembly and Arlington Assembly on Thursday and Friday. The Detroit automaker said Monday it...
Indivior Gets FDA Priority Review on Prior Approval Supplement for Sublocade
Indivior Gets FDA Priority Review on Prior Approval Supplement for Sublocade
Oct 7, 2024
12:38 PM EDT, 10/07/2024 (MT Newswires) -- Indivior ( INDV ) said Monday that the US Food and Drug Administration granted priority review designation to prior approval supplement for Sublocade injection. Sublocade is a monthly injectable formulation of buprenorphine from Indivior ( INDV ) for moderate to severe opioid use disorder treatment. The FDA has set a prescription drug user...
Copyright 2023-2026 - www.financetom.com All Rights Reserved